

**Title:** Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

**Short title:** Sex differences and antipsychotics

**Journal:** CNS Drugs

**Authors:**

**Megan Galbally**<sup>1,2</sup> ORCID [0000-0003-3909-1918](https://orcid.org/0000-0003-3909-1918)

**Karen Wynter**<sup>1,3</sup> ORCID [0000-0003-4620-7691](https://orcid.org/0000-0003-4620-7691)

**Dan Siskind**<sup>4,5</sup> ORCID [0000-0002-2072-9216](https://orcid.org/0000-0002-2072-9216)

**Christoph U. Correll**<sup>6,7,8,9</sup> ORCID [0000-0002-7254-5646](https://orcid.org/0000-0002-7254-5646)

**Korinne Northwood**<sup>4,5</sup> ORCID [0000-0001-6268-547X](https://orcid.org/0000-0001-6268-547X)

**Susanna Every-Palmer**<sup>10</sup> ORCID [0000-0001-6455-9741](https://orcid.org/0000-0001-6455-9741)

**Affiliations:**

1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

**Address Correspondence to:** Professor Megan Galbally, [megan.galbally@monash.edu](mailto:megan.galbally@monash.edu)

Supplementary Table 7: Self-reported presence of side effects at End of Phase by sex, within each treatment group

		Women n (%)	Men n (%)	$p^1$	$\phi$
Olanzapine (70 women, 171 men)	Akathisia	27 (38.6)	45 (26.3)	0.083	-0.122
	Akinesia	22 (31.4)	45 (26.3)	0.518	-0.052
	Constipation	22 (31.0)	23 (13.5)	0.003	-0.205
	Dry Mouth	34 (47.9)	61 (35.7)	0.104	-0.114
	Gynecomastia/Galactorrhea	7 (9.9)	8 (4.7)	0.219	-0.098
	Hypersomnia	11 (15.5)	31 (18.1)	0.759	0.032
	Incontinence/Nocturia	7 (9.9)	12 (7.0)	0.627	-0.048
	Insomnia	23 (32.9)	48 (28.1)	0.559	-0.048
	Orthostatic Faintness	18 (25.4)	39 (22.8)	0.796	-0.027
	Sex Drive	14 (20.0)	38 (22.2)	0.835	0.025
	Sexual Arousal	10 (14.3)	39 (22.8)	0.188	0.096
	Sexual Orgasm	8 (11.4)	28 (16.4)	0.436	0.063
	Sialorrhea	9 (12.7)	22 (12.9)	1.000	0.003
	Skin Rash	6 (8.5)	12 (7.0)	0.906	-0.025
	Sleepiness	35 (49.3)	79 (46.2)	0.766	-0.028
	Urinary Hesitancy	6 (8.5)	13 (7.6)	1.000	-0.014
	Weight Gain	33 (46.5)	56 (32.7)	0.061	-0.130
Perphenazine (47 women, 152 men)	Akathisia	14 (29.8)	55 (36.2)	0.529	0.057
	Akinesia	15 (31.9)	35 (23.0)	0.300	-0.087
	Constipation	7 (14.9)	17 (11.2)	0.670	-0.048
	Dry Mouth	19 (40.4)	53 (34.9)	0.604	-0.049
	Gynecomastia/Galactorrhea	4 (8.5)	4 (2.6)	0.171	-0.127
	Hypersomnia	7 (14.9)	28 (18.4)	0.737	0.039
	Incontinence/Nocturia	6 (12.8)	12 (7.9)	0.467	-0.072
	Insomnia	16 (34.0)	55 (36.2)	0.925	0.019
	Orthostatic Faintness	9 (19.1)	34 (22.4)	0.790	0.033
	Sex Drive	9 (19.1)	31 (20.5)	1.000	0.015
	Sexual Arousal	9 (19.1)	23 (15.3)	0.695	-0.044

Quetiapine (57 women, 188 men)	Sexual Orgasm	8 (17.0)	27 (14.8)	0.887	-0.027
	Sialorrhea	9 (19.1)	21 (13.8)	0.509	-0.063
	Skin Rash	3 (6.4)	10 (6.6)	1.000	0.003
	Sleepiness	22 (46.8)	68 (44.7)	0.935	-0.018
	Urinary Hesitancy	2 (4.3)	19 (12.5)	0.181	0.114
	Weight Gain	15 (31.9)	25 (16.4)	0.035	-0.164
	Akathisia	18 (31.6)	48 (25.5)	0.465	-0.058
	Akinesia	15 (26.3)	43 (23.0)	0.735	-0.033
	Constipation	20 (35.1)	43 (22.8)	0.090	-0.119
	Dry Mouth	31 (54.4)	89 (47.1)	0.415	-0.062
	Gynecomastia/Galactorrhea	3 (5.4)	5 (2.6)	0.565	-0.064
	Hypersomnia	11 (19.3)	27 (14.3)	0.478	-0.059
	Incontinence/Nocturia	6 (10.5)	15 (7.9)	0.732	-0.039
	Insomnia	16 (28.1)	51 (27.3)	1.000	-0.008
	Orthostatic Faintness	19 (33.3)	57 (30.2)	0.771	-0.029
	Sex Drive	11 (19.3)	35 (18.5)	1.000	-0.008
	Sexual Arousal	8 (14.3)	37 (19.6)	0.483	0.057
	Sexual Orgasm	8 (14.3)	27 (14.5)	1.000	0.003
	Sialorrhea	6 (10.5)	20 (10.6)	1.000	0.001
	Risperidone (68 women, 183 men)	Skin Rash	10 (17.5)	19 (10.1)	0.193
Sleepiness		28 (50.0)	87 (45.8)	0.687	-0.035
Urinary Hesitancy		5 (8.8)	22 (11.6)	0.715	0.039
Weight Gain		18 (31.6)	48 (25.5)	0.465	-0.058
Akathisia		27 (39.7)	56 (30.6)	0.226	-0.086
Akinesia		23 (33.8)	58 (31.7)	0.866	-0.020
Constipation		19 (27.9)	24 (13.2)	0.010	-0.174
Dry Mouth		38 (55.9)	61 (33.3)	0.002	-0.205
Gynecomastia/Galactorrhea		13 (18.8)	5 (2.7)	<0.001	-0.279
Hypersomnia		13 (19.1)	27 (14.8)	0.519	-0.053
Incontinence/Nocturia	19 (27.9)	14 (7.7)	<0.001	-0.267	
Insomnia	32 (47.1)	55 (30.1)	0.018	-0.159	

Ziprasidone (37 women, 89 men)	Orthostatic Faintness	24 (35.3)	61 (33.3)	0.887	-0.018
	Sex Drive	14 (20.6)	40 (21.7)	0.980	0.012
	Sexual Arousal	14 (20.6)	46 (25.1)	0.559	0.047
	Sexual Orgasm	12 (17.6)	39 (21.3)	0.642	0.040
	Sialorrhea	14 (20.6)	27 (14.8)	0.358	-0.070
	Skin Rash	9 (13.2)	20 (10.9)	0.775	-0.032
	Sleepiness	36 (52.9)	67 (36.6)	0.028	-0.148
	Urinary Hesitancy	8 (11.8)	15 (8.2)	0.532	0.047
	Weight Gain	28 (41.2)	41 (22.4)	0.004	-0.187
	Akathisia	9 (24.3)	37 (41.6)	0.103	0.163
	Akinesia	6 (16.2)	23 (25.8)	0.349	0.104
	Constipation	9 (24.3)	14 (15.7)	0.377	-0.101
	Dry Mouth	18 (48.6)	35 (39.3)	0.428	-0.086
	Gynecomastia/Galactorrhea	3 (8.1)	4 (4.5)	0.704	-0.072
	Hypersomnia	4 (10.8)	9 (10.1)	1.000	-0.010
	Incontinence/Nocturia	6 (16.2)	6 (6.7)	0.188	-0.147
	Insomnia	16 (43.2)	35 (39.3)	0.835	-0.036
	Orthostatic Faintness	11 (29.7)	20 (22.5)	0.526	-0.077
	Sex Drive	5 (13.5)	19 (21.6)	0.425	0.094
	Sexual Arousal	3 (8.1)	17 (19.1)	0.204	0.137
	Sexual Orgasm	4 (10.8)	14 (15.7)	0.661	0.064
	Sialorrhea	8 (21.6)	12 (13.5)	0.384	-0.101
	Skin Rash	6 (16.2)	6 (6.7)	0.188	-0.147
	Sleepiness	17 (45.9)	32 (36.0)	0.397	-0.093
	Urinary Hesitancy	3 (8.1)	10 (11.2)	0.838	0.047
	Weight Gain	10 (27.0)	15 (16.9)	0.223	-0.116

<sup>1</sup> *p*-values and effect sizes associated with  $\chi^2$  tests.

Note: some expected cell counts are <5, interpret results with caution